Lario gets $2.4m to push brain-targeted drugs further
Lario Therapeutics won $2.4 million in grants from the Michael J. Fox Foundation and Wellcome to advance CaV1.3 and CaV2.3 calcium-channel drug programs toward Parkinson's disease, PTSD and severe developmental epileptic encephalopathies, with IND-enabling studies planned for 2026.
Why it mattersThis financing signal shows where investor conviction is concentrating and which longevity business models are most likely to secure future capital.